Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 2
1956 2
1957 1
1964 2
1965 1
1985 1
1988 3
1989 3
1990 1
1991 2
1992 2
1994 2
1995 3
1996 12
1997 6
1998 2
1999 6
2000 4
2001 3
2002 3
2003 12
2004 15
2005 11
2006 18
2007 22
2008 22
2009 14
2010 40
2011 39
2012 47
2013 58
2014 74
2015 89
2016 87
2017 109
2018 110
2019 118
2020 143
2021 165
2022 180
2023 184
2024 48

Text availability

Article attribute

Article type

Publication date

Search Results

1,517 results

Results by year

Filters applied: . Clear all
Page 1
Investigational Treatments for Epidermolysis Bullosa.
Hou PC, Wang HT, Abhee S, Tu WT, McGrath JA, Hsu CK. Hou PC, et al. Am J Clin Dermatol. 2021 Nov;22(6):801-817. doi: 10.1007/s40257-021-00626-3. Epub 2021 Jul 22. Am J Clin Dermatol. 2021. PMID: 34292508 Review.
Macrophage polarization and metabolism in atherosclerosis.
Hou P, Fang J, Liu Z, Shi Y, Agostini M, Bernassola F, Bove P, Candi E, Rovella V, Sica G, Sun Q, Wang Y, Scimeca M, Federici M, Mauriello A, Melino G. Hou P, et al. Cell Death Dis. 2023 Oct 20;14(10):691. doi: 10.1038/s41419-023-06206-z. Cell Death Dis. 2023. PMID: 37863894 Free PMC article. Review.
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.
Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, Ruiz SH, Soto LS, Parra E, Ying H, Han J, Dey P, Li J, Deng P, Sei E, Maeda DY, Zebala JA, Spring DJ, Kim M, Wang H, Maitra A, Moore D, Clise-Dwyer K, Wang YA, Navin NE, DePinho RA. Gulhati P, et al. Among authors: hou p. Nat Cancer. 2023 Jan;4(1):62-80. doi: 10.1038/s43018-022-00500-z. Epub 2022 Dec 30. Nat Cancer. 2023. PMID: 36585453 Free PMC article.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Weber JS, et al. Among authors: hou p. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
1,517 results